Genetically engineered anti-CD20-IFN-α fusion proteins exert direct cytotoxicity and overcome CD20 mAb resistance in mice bearing B-cell lymphoma xenografts [58]. Here, IFNA1 is linked to B-cell non-Hodgkin lymphoma.